Literature DB >> 1255322

Variance in albumin loading in exchange transfusions.

G Chan, D Schiff.   

Abstract

To assess the rationale of albumin priming prior to exchange transfusions, 42 hyperbilirubinemic infants who required exchange transfusions were randomly assigned to one of two groups. Group I consisted of 15 infants who were given intravenously 1 gm/kg of salt-poor human serum albumin one hour before the exchanges. Group II, which consisted of 27 infants, received simple exchanges. No statistical differences were found in variations in reserve albumin-binding capacity, bilirubin, albumin, or red cell bilirubin at pre and one-hour post albumin infusion in the primed infants. The amount of bilirubin removed per kilogram is directly correlated to plasma bilirubin concentration (r=0.87). No significant difference in efficiency on bilirubin removal was seen between the two groups. Beneficial effects of albumin therapy was apparent only in those infants with low RABC as determined by the sephadex gel filtration technique.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1255322     DOI: 10.1016/s0022-3476(76)80020-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  4 in total

1.  The use of plasma in the neonatal period.

Authors:  G McClure
Journal:  Arch Dis Child       Date:  1991-04       Impact factor: 3.791

Review 2.  Early volume expansion for prevention of morbidity and mortality in very preterm infants.

Authors:  D A Osborn; N Evans
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 3.  Management of neonatal hyperbilirubinaemia and prevention of kernicterus.

Authors:  F F Rubaltelli; P F Griffith
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

4.  Optimizing exchange transfusion for severe unconjugated hyperbilirubinemia: studies in the Gunn rat.

Authors:  Andrea B Schreuder; Jana Vanikova; Libor Vitek; Rick Havinga; Charles E Ahlfors; Christian V Hulzebos; Henkjan J Verkade
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.